Abstract
The cardiovascular risk of patients undergoing dialysis is 20–30 times higher than that of individuals of the same age, without abnormal renal function, from the general population. Observational studies of patients with normal and abnormal renal function have shown that there is an association between bone disease, vascular calcification and cardiovascular outcome and that worsening of these conditions happens in parallel. Basic science studies are elucidating several mechanisms that could explain the interaction between bone disease, vascular calcification and cardiovascular outcome. For example, the expression of osteoprotegerin—a protein that regulates bone resorption by binding receptor activator of nuclear factor κB (RANK) ligand (RANKL), thus preventing interaction with the receptor RANK and the stimulation of osteoclast maturation—is regulated by several cytokines. Additionally, osteoprotegerin seems involved in the genesis of atherosclerosis. Imbalances of bone mineral metabolism, bone matrix secretion and vascular smooth-muscle-cell apoptosis seem involved in the ossification of the arterial wall in chronic kidney disease, and could explain some of the complex interactions between bone and vascular disease in renal failure. In this article we present a brief review of some of the basic mechanisms involved in vascular calcification and the clinical evidence of an association of vascular and bone disease.
Key Points
-
Clinical, epidemiological and basic science studies indicate that arterial and bone disease are closely interconnected
-
Vascular calcification is a well established marker of arteriopathy and is associated with poor outcome in the general population as well as in dialysis patients
-
Vascular calcification, probably secondary to an active process resembling bone formation, often accompanies worsening bone density
-
An association between bone loss and increased cardiovascular risk has been documented in postmenopausal women and elderly men, and seems particularly relevant in patients with chronic kidney disease
-
In patients with chronic kidney disease, abnormalities of calcium and phosphorus metabolism, as well as use of calcium containing phosphate binders have been associated with severity and progression of arterial calcification and adverse long-term outcome
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hunt JL et al. (2002) Bone formation in carotid plaques: a clinicopathological study. Stroke 33: 1214–1219
Mohler ER III et al. (2001) Bone formation and inflammation in cardiac valves. Circulation 103: 1522–1528
Jono S et al. (2002) Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 106: 1192–1194
Simonet WS et al. (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309–319
Speer MY and Giachelli CM (2004) Regulation of cardiovascular calcification. Cardiovasc Pathol 13: 63–70
Ketteler M (2005) Fetuin-A and extraosseous calcification in uremia. Curr Opin Nephrol Hypertens 14: 337–342
Luo G et al. (1997) Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386: 78–81
Hur DJ et al. (2005) A novel MGP mutation in a consanguineous family: review of the clinical and molecular characteristics of Keutel syndrome. Am J Med Genet A 135: 36–40
Murshed M et al. (2004) Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J Cell Biol 165: 625–630
Coates T et al. (1998) Cutaneous necrosis from calcific uremic arteriolopathy. Am J Kidney Dis 32: 384–391
Beitz JM (2003) Calciphylaxis: a case study with differential diagnosis. Ostomy Wound Manage 49: 28–38
Price PA et al. (2000) Warfarin-induced artery calcification is accelerated by growth and vitamin D. Arterioscler Thromb Vasc Biol 20: 317–327
Essalihi R et al. (2003) A new model of isolated systolic hypertension induced by chronic warfarin and vitamin K1 treatment. Am J Hypertens 16: 103–110
Jono S et al. (2004) Matrix Gla protein is associated with coronary artery calcification as assessed by electron-beam computed tomography. Thromb Haemost 91: 790–794
Moe SM et al. (2005) Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int 67: 2295–2304
Schafer C et al. (2003) The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 112: 357–366
Ketteler M et al. (2003) Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 361: 827–833
Mehrotra R et al. (2005) Serum fetuin-A in nondialyzed patients with diabetic nephropathy: relationship with coronary artery calcification. Kidney Int 67: 1070–1077
Rutsch F et al. (2003) Mutations in ENPP1 are associated with 'idiopathic' infantile arterial calcification. Nat Genet 34: 379–381
Rutsch F et al. (2001) PC-1 nucleoside triphosphate pyrophosphohydrolase deficiency in idiopathic infantile arterial calcification. Am J Pathol 158: 543–554
Harmey D et al. (2004) Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: an integrated model of the pathogenesis of mineralization disorders. Am J Pathol 164: 1199–1209
Johnson K et al. (2005) Chondrogenesis mediated by PPi depletion promotes spontaneous aortic calcification in NPP1−/− mice. Arterioscler Thromb Vasc Biol 25: 686–691
Lomashvili KA et al. (2005) Reduced plasma pyrophosphate levels in hemodialysis patients. J Am Soc Nephrol 16: 2495–2500
Steitz SA et al. (2001) Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 89: 1147–1154
Chen NX et al. (2002) Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int 62: 1724–1731
Moe SM et al. (2003) Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int 63: 1003–1011
Moe SM et al. (2002) Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 61: 638–647
Kim KM (1976) Calcification of matrix vesicles in human aortic valve and aortic media. Fed Proc 35: 156–162
Proudfoot D et al. (2000) Apoptosis regulates human vascular calcification in vitro: evidence for initiation of vascular calcification by apoptotic bodies. Circ Res 87: 1055–1062
Reynolds JL et al. (2004) Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 15: 2857–2867
Bucay N et al. (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12: 1260–1268
Price PA et al. (2001) Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 21: 817–824
Price PA et al. (2001) Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol 21: 1610–1616
Price PA et al. (2002) SB 242784, a selective inhibitor of the osteoclastic V-H+ ATPase, inhibits arterial calcification in the rat. Circ Res 91: 547–552
Banks LM et al. (1994) Effect of degenerative spinal and aortic calcification on bone density measurements in post-menopausal women: links between osteoporosis and cardiovascular disease? Eur J Clin Invest 24: 813–817
McFarlane SI et al. (2004) Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link? Endocrine 23: 1–10
van Meurs JB et al. (2004) Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 350: 2033–2041
Mantovani A et al. (1997) Endothelial activation by cytokines. Ann NY Acad Sci 832: 93–116
Cohen-Solal ME et al. (1993) Peripheral monocyte culture supernatants of menopausal women can induce bone resorption: involvement of cytokines. J Clin Endocrinol Metab 77: 1648–1653
Mundy G et al. (1999) Stimulation of bone formation in vitro and in rodents by statins. Science 286: 1946–1949
Edwards CJ et al. (2000) Oral statins and increased bone-mineral density in postmenopausal women. Lancet 355: 2218–2219
Meier CR et al. (2000) Statin drugs and the risk of fracture. JAMA 284: 1921–1922
von der Recke P et al. (1999) The association between low bone mass at the menopause and cardiovascular mortality. Am J Med 106: 273–278
Kado DM et al. (2000) Rate of bone loss is associated with mortality in older women: a prospective study. J Bone Miner Res 15: 1974–1980
Tanko LB et al. (2005) Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res 20: 1912–1920
Barrett-Connor E et al. (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355: 125–137
Samelson EJ et al. (2004) Metacarpal cortical area and risk of coronary heart disease: the Framingham Study. Am J Epidemiol 159: 589–595
van der Klift M et al. (2002) Bone mineral density and the risk of peripheral arterial disease: the Rotterdam Study. Calcif Tissue Int 70: 443–449
Mussolino ME et al. (2003) Bone mineral density and mortality in women and men: the NHANES I epidemiologic follow-up study. Ann Epidemiol 13: 692–697
Magnus JH and Broussard DL (2005) Relationship between bone mineral density and myocardial infarction in US adults. Osteoporos Int 16: 2053–2062
Trivedi DP and Khaw KT (2001) Bone mineral density at the hip predicts mortality in elderly men. Osteoporos Int 12: 259–265
Marcovitz PA et al. (2005) Usefulness of bone mineral density to predict significant coronary artery disease. Am J Cardiol 96: 1059–1063
Uyama O et al. (1997) Bone changes and carotid atherosclerosis in postmenopausal women. Stroke 28: 1730–1732
Sinnott B et al. (2006) Coronary calcification and osteoporosis in men and postmenopausal women are independent processes associated with aging. Calcif Tissue Int 78: 195–202
Aoyagi K et al. (2001) Low bone density is not associated with aortic calcification. Calcif Tissue Int 69: 20–24
Kiel DP et al. (2001) Bone loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham Heart Study. Calcif Tissue Int 68: 271–276
Hak AE et al. (2000) Progression of aortic calcification is associated with metacarpal bone loss during menopause: a population-based longitudinal study. Arterioscler Thromb Vasc Biol 20: 1926–1931
Schulz E et al. (2004) Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab 89: 4246–4253
Fukagawa M et al. (2002) Renal osteodystrophy and secondary hyperparathyroidism. Nephrol Dial Transplant 17 (Suppl 10): S2–S5
Moe SM (2001) Current issues in the management of secondary hyperparathyroidism and bone disease. Perit Dial Int 21 (Suppl 3): S241–S246
Parfitt AM (1997) The hyperparathyroidism of chronic renal failure: a disorder of growth. Kidney Int 52: 3–9
Morii H et al. (2004) Management of calcium and bone abnormalities in hemodialysis patients. Semin Nephrol 24: 446–448
Block GA et al. (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208–2218
Stevens LA et al. (2004) Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 15: 770–779
Li X et al. (2006) Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res 98: 905–912
Jono S et al. (2000) Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87: E10–E17
Block GA et al. (2005) Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68: 1815–1824
Raggi P et al. (2002) Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 39: 695–701
Matsuoka M et al. (2004) Impact of high coronary artery calcification score (CACS) on survival in patients on chronic hemodialysis. Clin Exp Nephrol 8: 54–58
Blacher J et al. (2001) Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38: 938–942
Chertow GM et al. (2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62: 245–252
Raggi P et al. (2005) Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis. J Bone Miner Res 20: 764–772
London GM et al. (2004) Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 15: 1943–1951
Taal MW et al. (2003) Total hip bone mass predicts survival in chronic hemodialysis patients. Kidney Int 63: 1116–1120
Raggi P et al. (2004) Valvular calcification in hemodialysis patients randomized to calcium-based phosphorus binders or sevelamer. J Heart Valve Dis 13: 134–141
Nitta K et al. (2004) Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. Am J Kidney Dis 44: 680–688
Teng M et al. (2003) Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349: 446–456
Watson KE et al. (1997) Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation 96: 1755–1760
Hruska KA et al. (2005) Bone morphogenetic proteins in vascular calcification. Circ Res 97: 105–114
Callister TQ et al. (1998) Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med 339: 1972–1978
Bekker PJ et al. (2004) A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19: 1059–1066
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
P Raggi has received honoraria and research grants from and is part of a medical advisory board for Genzyme Therapeutics, Cambridge, MA, USA.
C Giachelli is part of a medical advisory board for Genzyme Therapeutics, Cambridge, MA, USA.
A Bellasi declared he has no competing interests.
Rights and permissions
About this article
Cite this article
Raggi, P., Giachelli, C. & Bellasi, A. Interaction of vascular and bone disease in patients with normal renal function and patients undergoing dialysis. Nat Rev Cardiol 4, 26–33 (2007). https://doi.org/10.1038/ncpcardio0725
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpcardio0725
This article is cited by
-
Bone kidney interactions
Reviews in Endocrine and Metabolic Disorders (2015)
-
The influence of vitamin D analogs on calcification modulators, N-terminal pro-B-type natriuretic peptide and inflammatory markers in hemodialysis patients: a randomized crossover study
BMC Nephrology (2014)
-
Inverse Correlation Between Vascular Calcification and Bone Mineral Density in Human Immunodeficiency Virus-Infected Patients
Calcified Tissue International (2013)
-
Calcium-sensing receptor, calcimimetics, and cardiovascular calcifications in chronic kidney disease
Kidney International (2012)
-
The Aging Skeleton: Differences Between HIV-Infected Patients and the Uninfected Aging Population
Clinical Reviews in Bone and Mineral Metabolism (2012)